Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Caribbean Blue Scorpion Peptides Derived Extract
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Escozine (Caribbean Blue Scorpion Peptides Derived Extract), a proprietary formulation consisting of small molecule peptides derived from Rhopalurus princeps scorpions, is being researched as a treatment of various indications, including COVID-19 and can...
Product Name : Escozine
Product Type : Peptide
Upfront Cash : Inapplicable
November 01, 2022
Lead Product(s) : Caribbean Blue Scorpion Peptides Derived Extract
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Ibuprofen
Therapeutic Area : Neurology
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : The results showed an increase of COX-2 inhibition in the polarized sample when compared to the non-polarized sample, where the inhibition was 257.67% higher than the non-polarized sample of ibuprofen.
Product Name : Ibuprofen-Generic
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
December 10, 2021
Lead Product(s) : Ibuprofen
Therapeutic Area : Neurology
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Caribbean Blue Scorpion Peptides Derived Extract
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Physicians observed that patients who originally had strong adverse reactions to COVID-19 vaccines and who were given Escozine®, experienced significantly lessened side effects.
Product Name : Escozine
Product Type : Peptide
Upfront Cash : Inapplicable
August 07, 2021
Lead Product(s) : Caribbean Blue Scorpion Peptides Derived Extract
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Caribbean Blue Scorpion Peptides Derived Extract
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Undisclosed
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
FDA Accepts COVID-19 Clinical Study and Advises on Next Steps for Pre-IND Filing by Medolife Rx
Details : The response included: recognition from the FDA on the therapeutic effects of Escozine®, validation of the Company’s clinical trial as an informal proof-of-concept study, and laid out very specific guidelines for regulatory approval of Escozine®.
Product Name : Escozine
Product Type : Peptide
Upfront Cash : Inapplicable
June 23, 2021
Lead Product(s) : Caribbean Blue Scorpion Peptides Derived Extract
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Undisclosed
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Scorpion venom
Therapeutic Area : Oncology
Study Phase : Undisclosed
Sponsor : Ministry of Environment of The Dominican Republic
Deal Size : Undisclosed
Deal Type : Partnership
Details : Medolife and The Ministry of Environment of The Dominican Republic signed an exclusive 10-year agreement with automatic renewal. The partnership grants exclusive rights for investigations, production, and distribution world-wide for a Scorpion venom to t...
Product Name : Undisclosed
Product Type : Peptide
Upfront Cash : Undisclosed
January 21, 2021
Lead Product(s) : Scorpion venom
Therapeutic Area : Oncology
Highest Development Status : Undisclosed
Sponsor : Ministry of Environment of The Dominican Republic
Deal Size : Undisclosed
Deal Type : Partnership